Focus: ANI Pharmaceuticals is a public CDMO and generics manufacturer headquartered in Baudette, Minnesota, with a portfolio of branded and generic drugs generating $487M in FY2025 revenue.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow ANI Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Largest revenue contributor at 33% of total sales but approaching loss of exclusivity with no disclosed LOE date, creating significant near-term revenue risk.
Help build intelligence for ANI Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ANI Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Second-largest product but already post-LOE, generating steady generic competition and declining revenue stream.
Third-largest branded product with LOE approaching; represents moderate near-term patent cliff exposure.
Modest oncology revenue but LOE approaching; consistent with portfolio-wide patent cliff pattern.
Extended-release formulation with small revenue base but LOE approaching, contributing to cumulative patent cliff exposure.
248 discontinued, 48 duplicate formulations not shown
+3 more products with revenue data
Assessing ANI Pharmaceuticals (ANIP) Valuation After New U.S. Generic Drug Launches - Yahoo Finance
Assessing ANI Pharmaceuticals (ANIP) Valuation After New U.S. Generic Drug Launches Yahoo Finance
Best Pharmaceutical Stocks to Buy for April 2026 - Zacks Investment Research
Best Pharmaceutical Stocks to Buy for April 2026 Zacks Investment Research
ANIP Price Today: ANI Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
ANIP Price Today: ANI Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC MEXC Exchange
ANI Pharmaceuticals launches generic Orap - Drug Store News
ANI Pharmaceuticals launches generic Orap Drug Store News
ANI launches generic Orap drug with 180 days of exclusivity - Stock Titan
ANI launches generic Orap drug with 180 days of exclusivity Stock Titan
ANI Pharmaceuticals News Highlights Undervalued Shares And New Specialty Generics - simplywall.st
ANI Pharmaceuticals News Highlights Undervalued Shares And New Specialty Generics simplywall.st
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study.
Rapid biomonitoring of fluoropyrimidine-based chemotherapy drugs and their biometabolites in colorectal cancer patients' blood samples using an in-syringe-based fast drug extraction technique followed by LC-MS/MS analysis.
+47 more products
+2 more
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo